Regulus Therapeutics

Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer

Retrieved on: 
Wednesday, January 3, 2024
Health, Hospitals, Genetics, General Health, Pharmaceutical, Biotechnology, RNA, Senior, Science, Drug discovery, Regulus Therapeutics, TANGO, Iron monosilicide, Research, Acquisition, Therapy, Novartis, Medicinal chemistry, CNS, Bangladesh Technical Education Board, Conditional, Central nervous system, Pharma, Lafayette College, Harvard University, Vaccine

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat diseases utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat diseases utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).
  • He succeeds Si-ping Han, Ph.D., co-founder of Switch Therapeutics, who will transition to an advisory role and serve on Switch’s Scientific Advisory Board.
  • “Charles joins our leadership team with extensive expertise in oligonucleotide chemistry and RNA-based therapeutics, and we are delighted to welcome him to Switch.
  • He will play a crucial role as we continue driving our novel CASi platform forward for the treatment of central nervous system (CNS) diseases,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
Wednesday, November 22, 2023
MicroRNA, Regulus Therapeutics, SAN, Conference, Therapy, Pharmaceutical industry, Online shopping

SAN DIEGO, Nov. 22, 2023 /PRNewswire/ -- Regulus Therapeutics Inc .

Key Points: 
  • SAN DIEGO, Nov. 22, 2023 /PRNewswire/ -- Regulus Therapeutics Inc .
  • (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan will be participating in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday November 29, at 10:25 a.m.
  • ET.
  • A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
FDA, Research, Prader–Willi syndrome, Food, Therapy, Rare, Shire (pharmaceutical company), CMC, HQ, Drug, Regulus Therapeutics, Endocrinology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Exercise, Insming, Bristol Myers Squibb, Neurology, PWS, NDA, Johnson & Johnson, Pharmaceutical industry, Medical imaging, Security (finance), Cryptocurrency

REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.
  • Presented results from the randomized withdrawal phase of Study C602 at the Foundation for Prader-Willi Research (FPWR) 2023 Research Symposium held on October 5-6, 2023 in Denver, Colorado.
  • “The recent announcement of positive results from the randomized withdrawal phase of Study C602 was a significant milestone for us,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics.
  • The following table summarizes the Soleno’s outstanding common stock and common stock warrants as of October 31, 2023:

Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Retrieved on: 
Wednesday, August 2, 2023
Canaccord Genuity, Therapy, MicroRNA, Conference, SAN, Regulus Therapeutics, Pharmaceutical industry

SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- Regulus Therapeutics Inc .

Key Points: 
  • SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- Regulus Therapeutics Inc .
  • (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan will be presenting at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 11:30 a.m.
  • ET.
  • A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 120 days following the presentation date.

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors

Retrieved on: 
Friday, June 23, 2023
Orexigen Therapeutics, Amgen, Duke University Hospital, University, Senior, University of Nebraska Medical Center, Internal medicine, Arena Pharmaceuticals, Nephrology, Nebraska Medicine, MicroRNA, CMO, Science, Regulus Therapeutics, SAN, ADPKD, Therapy, Transgene (company), Management, Research, Regulus

"We are delighted to have Dr. Klassen join our board during this exciting time for Regulus, as we advance the clinical development of RGLS8429 for the treatment of ADPKD," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.

Key Points: 
  • "We are delighted to have Dr. Klassen join our board during this exciting time for Regulus, as we advance the clinical development of RGLS8429 for the treatment of ADPKD," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.
  • "His expertise in nephrology, along with his previous leadership and board experience in the industry, will make him an invaluable member, and we look forward to his contributions to Regulus and our science."
  • Preston Klassen, M.D., recently joined Regulus Therapeutics as President and Head of Research and Development.
  • Previously, while at Amgen, he held multiple leadership roles, including Executive Medical Director and Therapeutics Area Head for Nephrology.

Regulus Therapeutics Strengthens Research & Development Leadership

Retrieved on: 
Monday, June 12, 2023
Orexigen Therapeutics, Amgen, Employment, University, Duke University Hospital, Biochemistry, University of Nebraska Medical Center, Doctor of Philosophy, Internal medicine, Arena Pharmaceuticals, Senior, Nephrology, CMC, Nebraska Medicine, MicroRNA, CMO, Regulus Therapeutics, Chemistry, Cardinal Health, Patient, SAN, Regulus, Preston, Kidney, Amylin Pharmaceuticals, Therapy, Kidney disease, Pharmaceutical industry, Management, Indiana University, Allergan, ADPKD, Research

SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development. Dr. Klassen brings over 20 years of experience in leadership roles in both large and small biopharmaceutical companies. In addition, the Company announced the appointment of Curtis A. Monnig, Ph.D., to Vice President of CMC. 

Key Points: 
  • SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development.
  • "We are thrilled to welcome Dr. Klassen to the Regulus team," said Jay Hagan, Chief Executive Officer of Regulus Therapeutics.
  • Dr. Preston Klassen is an established nephrologist who brings years of experience in leadership, medical affairs, and research and development across multiple therapeutic areas.
  • Previously, while at Amgen, he held multiple leadership roles, including Executive Medical Director and Therapeutics Area Head for Nephrology.

Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference

Retrieved on: 
Thursday, February 9, 2023
SAN, MicroRNA, Therapy, Conference, Regulus Therapeutics, Pharmaceutical industry, Online shopping, Regulus

SAN DIEGO, Feb. 9, 2023 /PRNewswire/ -- Regulus Therapeutics Inc .

Key Points: 
  • SAN DIEGO, Feb. 9, 2023 /PRNewswire/ -- Regulus Therapeutics Inc .
  • (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 1:00 p.m.
  • ET.
  • A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 30 days following the presentation date.

Biotech Industry Leaders Join Deep Genomics Board of Directors and Scientific Advisory Board

Retrieved on: 
Friday, January 6, 2023
Health, Technology, Genetics, Artificial Intelligence, Pharmaceutical, Biotechnology, Ness, Sarepta, IPO, Organic acid, GlaxoSmithKline, Coronavirus Scientific Advisory Board (Turkey), RNA, CSO, Lead, Oncology, Oligonucleotide, Intellia Therapeutics, Art, FRSC, Drug discovery, Doctor of Philosophy, Therapy, Drug development, Pfizer, Molecular biology, Ionis Pharmaceuticals, SoftBank Group, IP Group, Investment, CFO, Sarepta Therapeutics, GSK, Genomics, Sirna Therapeutics, Patient, AstraZeneca, Biology, Atlas, Khosla Ventures, AI, DPU, Regeneron Pharmaceuticals, Moderna, Atlas Venture, PTC, Regulus Therapeutics, University, PTC Therapeutics, Pharmaceutical industry

and Mark Edbrooke, Ph.D. have joined the Scientific Advisory Board.

Key Points: 
  • and Mark Edbrooke, Ph.D. have joined the Scientific Advisory Board.
  • “These industry leaders will lend valuable support and advice to Deep Genomics as we advance our revolutionary AI drug discovery platform toward the goal of bringing programmable RNA medicines to patients,” said Brendan Frey, Ph.D., FRSC, Founder and CEO of Deep Genomics.
  • Chip has more than 20 years of experience leading innovative biotech companies and also serves as a Director of Axcella Health.
  • He is a serial biotech entrepreneur and investor, most notably having founded Intellia Therapeutics, Korro Bio and Liberate Bio.

Codagenix Announces Appointment of Paul Grint, MD, as Executive Chairman of its Board of Directors

Retrieved on: 
Thursday, December 15, 2022
Therapy, Chattogram Maa-O-Shishu Hospital Medical College, Innovation, University of California, San Diego, National academy, Internal medicine, MD, Bachelor, Cancer, National Academy of Sciences, Research, Commercialization, Bachelor of Medicine, Bachelor of Surgery, Forest Research Institute, Immunity, Senior, University of London, St Mary's Hospital Medical School, Regulus Therapeutics, University, Charing Cross Hospital Medical School, Pharmaceutical industry, Vaccine, Infection, Science, Medicine

"We are delighted to welcome Paul to our Board of Directors.

Key Points: 
  • "We are delighted to welcome Paul to our Board of Directors.
  • "Paul brings extensive expertise in research and development, operations, fundraising, and corporate governance along with years of Board experience with both public and private companies.
  • Dr. Grint has over 30 years of industry experience and was most recently Chief Executive Officer for Ampliphi Biosciences.
  • Prior to Ampliphi, Dr. Grint served as Chief Executive Officer and Chief Medical Officer of Regulus Therapeutics.

Regulus Therapeutics Announces Resignation of Board Member

Retrieved on: 
Monday, December 12, 2022
Risk factor (finance), ADPKD, Therapy, Security (finance), MicroRNA, Drug discovery, Biomedical Research, Toxicology, Form 10-Q, SimOS, Disease, COVID-19, Multimedia, Regulus Therapeutics, Risk, SAN, Management, Regulus

"On behalf of the Board and the whole team at Regulus, I would like to thank Simos for his impactful leadership during his tenure at Regulus," saidStelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.

Key Points: 
  • "On behalf of the Board and the whole team at Regulus, I would like to thank Simos for his impactful leadership during his tenure at Regulus," saidStelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.
  • "Since joining the Board, Simos, with his expertise in investment management and biomedical research, has provided the team with invaluable insights that have helped Regulus achieve milestones and position the company for long-term success."
  • "Simos has been a valuable member of our team and we have appreciated his experience, dedication and thoughtful guidance as a Board member," said Jay Hagan, President and Chief Executive Officer of Regulus Therapeutics.
  • Regulus Therapeutics Inc.(Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.